Tag : ALK+ NSCLC

CONFERENCE UPDATE

Alectinib prolongs OS and shows durable response in previously untreated advanced ALK+ NSCLC: Final OS analysis from the phase 3 ALEX study
The ALEX study's final analysis shows that first-line alectinib significantly improves overall survival and duration of response in untreated advanced ALK-positive non-small cell lung cancer (NSCLC) compared to crizotinib, reinforcing alectinib as the standard of care for these patients.

Professor Mok Shu Kam Tony

Chairman, Department of Clinical Oncology, The Chinese University of Hong Kong
First-line lorlatinib shows 5-year benefits in Asian patients with ALK+ NSCLC: Post-hoc analysis from the CROWN trial
Lorlatinib, a third-generation, brain-penetrant anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, demonstrates potent antitumor activity in patients with ALK-positive (ALK+) non-small cell lung carcinoma (NSCLC) and is approved as a first-line treatment in many countries. This post-hoc analysis presents long-term outcomes in the Asian subgroup of the CROWN study, following a 5-year observation period.